Literature DB >> 30631970

Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on the Next Blood Pressure Guidelines in Asia.

Naoki Nakagawa1, Naoyuki Hasebe2.   

Abstract

PURPOSE OF REVIEW: To estimate the impact of the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines for high blood pressure (BP) on the next hypertension guidelines in Asia. RECENT
FINDINGS: The 2017 ACC/AHA guidelines for high BP in adults changed the diagnostic threshold and the management goal of BP from 140/90 to 130/80 mmHg. Another characteristic of the new guideline is its focus on a practical approach for the effective management of hypertension by using home and ambulatory BP monitoring; this point is also recommended in the 2014 Japanese Society of Hypertension Guidelines for the Management of Hypertension. In Japan, the guidelines for hypertension management are currently under revision and will be released in the spring of 2019. The core concept of the 2019 Japanese Society of Hypertension Guidelines for the Management of Hypertension, i.e., early and tight BP control over 24 h, will contribute to target-organ protection and cardiovascular disease prevention for Asians.

Entities:  

Keywords:  Ambulatory blood pressure monitoring; Blood pressure; Ethnic differences; Guideline; Hypertension Paradox

Mesh:

Substances:

Year:  2019        PMID: 30631970     DOI: 10.1007/s11906-019-0906-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  25 in total

1.  Prevalence and determinants of prehypertension in a Japanese general population: the Jichi Medical School Cohort Study.

Authors:  Yukiko Ishikawa; Joji Ishikawa; Shizukiyo Ishikawa; Kazunori Kayaba; Yosikazu Nakamura; Kazuyuki Shimada; Eiji Kajii; Thomas G Pickering; Kazuomi Kario
Journal:  Hypertens Res       Date:  2008-07       Impact factor: 3.872

2.  Shattuck Lecture. The hypertension paradox--more uncontrolled disease despite improved therapy.

Authors:  Aram V Chobanian
Journal:  N Engl J Med       Date:  2009-08-27       Impact factor: 91.245

Review 3.  Isolated nocturnal hypertension: a disease masked in the dark.

Authors:  Yan Li; Ji-Guang Wang
Journal:  Hypertension       Date:  2012-12-17       Impact factor: 10.190

4.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014).

Authors:  Kazuaki Shimamoto; Katsuyuki Ando; Toshiro Fujita; Naoyuki Hasebe; Jitsuo Higaki; Masatsugu Horiuchi; Yutaka Imai; Tsutomu Imaizumi; Toshihiko Ishimitsu; Masaaki Ito; Sadayoshi Ito; Hiroshi Itoh; Hiroshi Iwao; Hisashi Kai; Kazuomi Kario; Naoki Kashihara; Yuhei Kawano; Shokei Kim-Mitsuyama; Genjiro Kimura; Katsuhiko Kohara; Issei Komuro; Hiroo Kumagai; Hideo Matsuura; Katsuyuki Miura; Ryuichi Morishita; Mitsuhide Naruse; Koichi Node; Yusuke Ohya; Hiromi Rakugi; Ikuo Saito; Shigeyuki Saitoh; Kazuyuki Shimada; Tatsuo Shimosawa; Hiromichi Suzuki; Kouichi Tamura; Norio Tanahashi; Takuya Tsuchihashi; Makoto Uchiyama; Shinichiro Ueda; Satoshi Umemura
Journal:  Hypertens Res       Date:  2014-04       Impact factor: 3.872

5.  Global Impact of 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From China.

Authors:  Ji-Guang Wang; Lisheng Liu
Journal:  Circulation       Date:  2018-02-06       Impact factor: 29.690

Review 6.  Consensus Document on Improving Hypertension Management in Asian Patients, Taking Into Account Asian Characteristics.

Authors:  Kazuomi Kario; Chen-Huan Chen; Sungha Park; Chang-Gyu Park; Satoshi Hoshide; Hao-Min Cheng; Qi-Fang Huang; Ji-Guang Wang
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

Review 7.  Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event.

Authors:  Kazuomi Kario
Journal:  Prog Cardiovasc Dis       Date:  2016-04-11       Impact factor: 8.194

Review 8.  Management of morning hypertension: a consensus statement of an Asian expert panel.

Authors:  Ji-Guang Wang; Kazuomi Kario; Chen-Huan Chen; Jeong-Bae Park; Satoshi Hoshide; Yong Huo; Hae-Young Lee; Yan Li; Masaki Mogi; Masanori Munakata; Sungha Park; Dingliang Zhu
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-16       Impact factor: 3.738

9.  Effect of Intensive Salt-Restriction Education on Clinic, Home, and Ambulatory Blood Pressure Levels in Treated Hypertensive Patients During a 3-Month Education Period.

Authors:  Masahiro Nakano; Kazuo Eguchi; Toshiko Sato; Atsuko Onoguchi; Satoshi Hoshide; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-01-06       Impact factor: 3.738

Review 10.  The Global Epidemic of the Metabolic Syndrome.

Authors:  Mohammad G Saklayen
Journal:  Curr Hypertens Rep       Date:  2018-02-26       Impact factor: 5.369

View more
  3 in total

1.  Development and Validation of a Self-Quantification Scale for Patients With Hypertension.

Authors:  Guiyue Ma; Zhuqing Zhong; Yinglong Duan; Zhiying Shen; Ning Qin; Dehua Hu
Journal:  Front Public Health       Date:  2022-05-02

2.  Comparison between unattended automated office blood pressure and conventional office blood pressure under the environment of health checkup among Japanese general population.

Authors:  Hirofumi Sakuma; Naoki Nakagawa; Kiwamu Horiuchi; Taiki Hayasaka; Keisuke Maruyama; Jun Sawada; Akiho Minoshima; Takayuki Fujino; Toshiharu Takeuchi; Nobuyuki Sato; Shinobu Osanai; Naoyuki Hasebe
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-15       Impact factor: 3.738

3.  Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study).

Authors:  Naoki Nakagawa; Nobuyuki Sato; Yasuaki Saijo; Hideo Morimoto; Satoshi Koyama; Yuji Ogawa; Kazumi Uekita; Junichi Maruyama; Takafumi Ohta; Yasuhiro Nakamura; Toshiharu Takeuchi; Naoyuki Hasebe
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-06       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.